

DAFTAR PUSTAKA

- Adom, MB, Taher, M, Mutalabisin, MF, Amri, MS, Abdul Kudus, MB, Wan Sulaiman, MWA, Sengupta, P & Susanti, D 2017, 'Chemical constituents and medical benefits of *Plantago* major', *Biomedicine & Pharmacotherapy*, vol. 96, pp. 348–360.
- Afendi, FM, Okada, T, Yamazaki, M, Hirai-Morita, A, Nakamura, Y, Nakamura, K, Ikeda, S, Takahashi, H, Altaf-Ul-Amin, Md, Darusman, LK, Saito, K & Kanaya, S 2012, 'KNAPSAcK Family Databases: Integrated Metabolite–Plant Species Databases for Multifaceted Plant Research', *Plant and Cell Physiology*, vol. 53, no. 2, pp. e1–e1.
- Agu, PC, Afiukwa, CA, Orji, OU, Ezech, EM, Ofoke, IH, Ogbu, CO, Ugwuja, EI & Aja, PM 2023, 'Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management', *Scientific Reports*, vol. 13, no. 1, p. 13398.
- Aksentijevich, I, D. Putnam, C, Remmers, EF, Mueller, JL, Le, J, Kolodner, RD, Moak, Z, Chuang, M, Austin, F, Goldbach-Mansky, R, Hoffman, HM & Kastner, DL 2007, 'The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model', *Arthritis & Rheumatism*, vol. 56, no. 4, pp. 1273–1285.
- Ammar, A, Cavill, R, Evelo, C & Willighagen, E 2022, 'PSnpBind: a database of mutated binding site protein–ligand complexes constructed using a multithreaded virtual screening workflow', *Journal of Cheminformatics*, vol. 14, no. 1, p. 8.
- An, Q, Hu, Q, Wang, B, Cui, W, Wu, F & Ding, Y 2017, 'Oleanolic acid alleviates diabetic rat carotid artery injury through the inhibition of NLRP3 inflammasome signaling pathways', *Molecular Medicine Reports*, vol. 16, no. 6, pp. 8413–8419.
- Andreeva, L, David, L, Rawson, S, Shen, C, Pasricha, T, Pelegrin, P & Wu, H 2021, 'NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation', *Cell*, vol. 184, no. 26, pp. 6299–6312.e22.
- Attique, S, Hassan, M, Usman, M, Atif, R, Mahboob, S, Al-Ghanim, K, Bilal, M & Nawaz, M 2019, 'A Molecular Docking Approach to Evaluate the Pharmacological Properties of Natural and Synthetic Treatment Candidates for Use against Hypertension', *International Journal of Environmental Research and Public Health*, vol. 16, no. 6, p. 923.
- Baig, MH, Ahmad, K, Rabbani, G, Danishuddin, M & Choi, I 2018, 'Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders', *Current Neuropharmacology*, vol. 16, no. 6, pp. 740–748.
- Barba-Ostria, C, Carrera-Pacheco, SE, Gonzalez-Pastor, R, Heredia-Moya, J, Mayorga-Ramos, A, Rodríguez-Pólit, C, Zúñiga-Miranda, J, Arias-Almeida, B & Guamán, LP 2022, 'Evaluation of Biological Activity of Natural Compounds: Current Trends and Methods', *Molecules*, vol. 27, no. 14, p. 4490.

- Bender, BJ, Gahbauer, S, Lutgens, A, Lyu, J, Webb, CM, Stein, RM, Fink, EA, Balias, TE, Carlsson, J, Irwin, JJ & Shoichet, BK 2021, 'A practical guide to large-scale docking', *Nature Protocols*, vol. 16, no. 10, pp. 4799–4832.
- Bianchi, ME 2007, 'DAMPs, PAMPs and alarmins: all we need to know about danger', *Journal of Leukocyte Biology*, vol. 81, no. 1, pp. 1–5.
- Blevins, HM, Xu, Y, Biby, S & Zhang, S 2022, 'The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases', *Frontiers in Aging Neuroscience*, vol. 14, p. 879021.
- Boniakowski, AE, Kimball, AS, Jacobs, BN, Kunkel, SL & Gallagher, KA 2017, 'Macrophage-Mediated Inflammation in Normal and Diabetic Wound Healing', *The Journal of Immunology*, vol. 199, no. 1, pp. 17–24.
- Chen, Z, Liu, Q, Zhu, Z, Xiang, F, Zhang, M, Wu, R & Kang, X 2020, 'Ursolic Acid Protects Against Proliferation and Inflammatory Response in LPS-Treated Gastric Tumour Model and Cells by Inhibiting NLRP3 Inflammasome Activation', *Cancer Management and Research*, vol. Volume 12, pp. 8413–8424.
- Claußen, H, Buning, C, Rarey, M & Lengauer, T 2001, 'FlexE: efficient molecular docking considering protein structure variations', *Journal of Molecular Biology*, vol. 308, no. 2, pp. 377–395.
- Coll, RC, Hill, JR, Day, CJ, Zamoshnikova, A, Boucher, D, Massey, NL, Chitty, JL, Fraser, JA, Jennings, MP, Robertson, AAB & Schroder, K 2019, 'MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition', *Nature Chemical Biology*, vol. 15, no. 6, pp. 556–559.
- Coll, RC, Robertson, AAB, Chae, JJ, Higgins, SC, Muñoz-Planillo, R, Inserra, MC, Vetter, I, Dungan, LS, Monks, BG, Stutz, A, Croker, DE, Butler, MS, Haneklaus, M, Sutton, CE, Núñez, G, Latz, E, Kastner, DL, Mills, KHG, Masters, SL, Schroder, K, Cooper, MA & O'Neill, LAJ 2015, 'A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases', *Nature Medicine*, vol. 21, no. 3, pp. 248–255.
- Dar, AM & Mir, S 2017, 'Molecular Docking: Approaches, Types, Applications and Basic Challenges', *Journal of Analytical & Bioanalytical Techniques*, vol. 08, no. 02, viewed 18 December 2023, <<https://www.omicsonline.org/open-access/molecular-docking-approaches-types-applications-and-basic-challenges-2155-9872-1000356.php?aid=88070>>.
- Dasari, N, Jiang, A, Skochdopole, A, Chung, J, Reece, EM, Vorstenbosch, J & Winocour, S 2021, 'Updates in Diabetic Wound Healing, Inflammation, and Scarring', *Seminars in Plastic Surgery*, vol. 35, no. 03, pp. 153–158.
- De Torre-Minguela, C, Mesa Del Castillo, P & Pelegrín, P 2017, 'The NLRP3 and Pypin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases', *Frontiers in Immunology*, vol. 8, viewed 1 May 2024, <<http://journal.frontiersin.org/article/10.3389/fimmu.2017.00043/full>>.
- Dekker, C, Mattes, H, Wright, M, Boettcher, A, Hinniger, A, Hughes, N, Kapps-Fouthier, S, Eder, J, Erbel, P, Stiefl, N, Mackay, A & Farady, CJ 2021,

- ‘Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition’, *Journal of Molecular Biology*, vol. 433, no. 24, p. 167309.
- Devi, RV, Sathya, SS & Coumar, MS 2015, ‘Evolutionary algorithms for de novo drug design – A survey’, *Applied Soft Computing*, vol. 27, pp. 543–552.
- Ding, N, Wei, B, Fu, X, Wang, C & Wu, Y 2020, ‘Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis’, *Frontiers in Pharmacology*, vol. 11, p. 591393.
- Dowds, TA, Masumoto, J, Zhu, L, Inohara, N & Núñez, G 2004, ‘Cryopyrin-induced Interleukin 1 β Secretion in Monocytic Cells’, *Journal of Biological Chemistry*, vol. 279, no. 21, pp. 21924–21928.
- Ducharme-Bénard, S, Roberge, G & Chapdelaine, H 2022, ‘A unique presentation of NLRP3-associated autoinflammatory disease: case report’, *BMC Rheumatology*, vol. 6, no. 1, p. 91.
- Feyfant, E, Sali, A & Fiser, A 2007, ‘Modeling mutations in protein structures’, *Protein Science*, vol. 16, no. 9, pp. 2030–2041.
- Flores, SC & Gerstein, MB 2011, ‘Predicting protein ligand binding motions with the conformation explorer’, *BMC Bioinformatics*, vol. 12, no. 1, p. 417.
- Fukunishi, Y, Yamashita, Y, Mashimo, T & Nakamura, H 2018, ‘Prediction of Protein–compound Binding Energies from Known Activity Data: Docking-score-based Method and its Applications’, *Molecular Informatics*, vol. 37, no. 6–7, p. 1700120.
- García-Ortegón, M, Simm, GNC, Tripp, AJ, Hernández-Lobato, JM, Bender, A & Bacallado, S 2022, ‘DOCKSTRING: Easy Molecular Docking Yields Better Benchmarks for Ligand Design’, *Journal of Chemical Information and Modeling*, vol. 62, no. 15, pp. 3486–3502.
- Gatfaoui, S, Sagaama, A, Issaoui, N, Roisnel, T & Marouani, H 2020, ‘Synthesis, experimental, theoretical study and molecular docking of 1-ethylpiperazine-1,4-dium bis(nitrate)’, *Solid State Sciences*, vol. 106, p. 106326.
- Ginwala, R, Bhavsar, R, Chigbu, DI, Jain, P & Khan, ZK 2019, ‘Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin’, *Antioxidants*, vol. 8, no. 2, p. 35.
- Gritsenko, A, Green, JP, Brough, D & Lopez-Castejon, G 2020, ‘Mechanisms of NLRP3 priming in inflammaging and age related diseases’, *Cytokine & Growth Factor Reviews*, vol. 55, pp. 15–25.
- Haddadian, Kazhal, Haddadian, Katayoon & Zahmatkash, M 2014, *A review of Plantago plant*, vol. 13, no. 4.
- He, B, Zhang, B, Wu, F, Wang, L, Shi, X, Qin, W, Lin, Y, Ma, S & Liang, J 2016, ‘Homoplantagin Inhibits Palmitic Acid-induced Endothelial Cells Inflammation by Suppressing TLR4 and NLRP3 Inflammasome’, *Journal of Cardiovascular Pharmacology*, vol. 67, no. 1, pp. 93–101.
- Hermawan, A, Putri, H & Utomo, RY 2020a, ‘Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance’, *Molecular Diversity*, vol. 24, no. 4, pp. 933–947.

- Hermawan, A, Putri, H & Utomo, RY 2021, 'Exploration of targets and molecular mechanisms of cinnamaldehyde in overcoming fulvestrant-resistant breast cancer: a bioinformatics study', *Network Modeling Analysis in Health Informatics and Bioinformatics*, vol. 10, no. 1, p. 30.
- Hermawan, A, Putri, H & Utomo, RY 2020b, 'Functional network analysis reveals potential repurposing of β -blocker atenolol for pancreatic cancer therapy', *DARU Journal of Pharmaceutical Sciences*, vol. 28, no. 2, pp. 685–699.
- Hesketh, M, Sahin, KB, West, ZE & Murray, RZ 2017, 'Macrophage Phenotypes Regulate Scar Formation and Chronic Wound Healing', *International Journal of Molecular Sciences*, vol. 18, no. 7, p. 1545.
- Hochheiser, IV, Pils, M, Hagelueken, G, Moecking, J, Marleaux, M, Brinkschulte, R, Latz, E, Engel, C & Geyer, M 2022, 'Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3', *Nature*, vol. 604, no. 7904, pp. 184–189.
- Hollingsworth, SA & Karplus, PA 2010, 'A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins', *BioMolecular Concepts*, vol. 1, no. 3–4, pp. 271–283.
- Hussan, F, Mansor, AS, Hassan, SN, Tengku Nor Effendy Kamaruddin, TgNT, Budin, SB & Othman, F 2015, 'Anti-Inflammatory Property of *Plantago major* Leaf Extract Reduces the Inflammatory Reaction in Experimental Acetaminophen-Induced Liver Injury', *Evidence-Based Complementary and Alternative Medicine*, vol. 2015, pp. 1–7.
- Jiang, H, He, H, Chen, Y, Huang, W, Cheng, J, Ye, J, Wang, A, Tao, J, Wang, C, Liu, Q, Jin, T, Jiang, W, Deng, X & Zhou, R 2017, 'Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders', *Journal of Experimental Medicine*, vol. 214, no. 11, pp. 3219–3238.
- Karas, LJ, Wu, C, Das, R & Wu, JI 2020, 'Hydrogen bond design principles', *WIREs Computational Molecular Science*, vol. 10, no. 6, p. e1477.
- Kelley, N, Jeltema, D, Duan, Y & He, Y 2019, 'The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation', *International Journal of Molecular Sciences*, vol. 20, no. 13, p. 3328.
- Kim, HW, Wang, M, Leber, CA, Nothias, L-F, Reher, R, Kang, KB, Van Der Hooft, JJJ, Dorrestein, PC, Gerwick, WH & Cottrell, GW 2021, 'NPClassifier: A Deep Neural Network-Based Structural Classification Tool for Natural Products', *Journal of Natural Products*, vol. 84, no. 11, pp. 2795–2807.
- L'homme, L, Esser, N, Riva, L, Scheen, A, Paquot, N, Piette, J & Legrand-Poels, S 2013, 'Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages', *Journal of Lipid Research*, vol. 54, no. 11, pp. 2998–3008.
- Liang, X, Zhao, Y, Xu, T, Wang, W, Sun, W & Wang, R 2023, 'Catalpol Alleviates Depression by Inhibiting NLRP3 Inflammasome via TLR4/MAPK/NF- κ B Pathway', *Iranian Journal of Public Health*, viewed 2 January 2024, <<https://publish.kne-publishing.com/index.php/ijph/article/view/12440>>.
- Lim, H, Min, DS, Park, H & Kim, HP 2018, 'Flavonoids interfere with NLRP3 inflammasome activation', *Toxicology and Applied Pharmacology*, vol. 355, pp. 93–102.

- Lin, C, Jiang, Z, Cao, L, Zou, H & Zhu, X 2022, 'Role of NLRP3 inflammasome in systemic sclerosis', *Arthritis Research & Therapy*, vol. 24, no. 1, p. 196.
- Liu, B & Yu, J 2021, 'Anti-NLRP3 Inflammasome Natural Compounds: An Update', *Biomedicines*, vol. 9, no. 2, p. 136.
- Lv, D, Cao, X, Zhong, L, Dong, Y, Xu, Z, Rong, Y, Xu, H, Wang, Z, Yang, H, Yin, R, Chen, M, Ke, C, Hu, Z, Deng, W & Tang, B 2023, 'Targeting phenylpyruvate restrains excessive NLRP3 inflammasome activation and pathological inflammation in diabetic wound healing', *Cell Reports Medicine*, vol. 4, no. 8, p. 101129.
- Ma, Q 2023, 'Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction', J Schuetz (ed.), *Pharmacological Reviews*, vol. 75, no. 3, pp. 487–520.
- Mahmud, S, Morehead, A & Cheng, J 2023, *Accurate prediction of protein tertiary structural changes induced by single-site mutations with equivariant graph neural networks*, viewed 1 May 2024, <<http://biorxiv.org/lookup/doi/10.1101/2023.10.03.560758>>.
- Majewski, M, Ruiz-Carmona, S & Barril, X 2019, 'An investigation of structural stability in protein-ligand complexes reveals the balance between order and disorder', *Communications Chemistry*, vol. 2, no. 1, p. 110.
- Malik, A & Kanneganti, T-D 2017, 'Inflammasome activation and assembly at a glance', *Journal of Cell Science*, vol. 130, no. 23, pp. 3955–3963.
- Marchetti, C, Chojnacki, J, Toldo, S, Mezzaroma, E, Tranchida, N, Rose, SW, Federici, M, Van Tassell, BW, Zhang, S & Abbate, A 2014, 'A Novel Pharmacologic Inhibitor of the NLRP3 Inflammasome Limits Myocardial Injury After Ischemia–Reperfusion in the Mouse', *Journal of Cardiovascular Pharmacology*, vol. 63, no. 4, pp. 316–322.
- Matsuura, N, Aradate, T, Kurosaka, C, Ubukata, M, Kittaka, S, Nakaminami, Y, Gamo, K, Kojima, H & Ohara, M 2014, 'Potent Protein Glycation Inhibition of Plantagoside in *Plantago major* Seeds', *BioMed Research International*, vol. 2014, pp. 1–5.
- Meng, X-Y, Zhang, H-X, Mezei, M & Cui, M 2011, 'Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery', *Current Computer Aided-Drug Design*, vol. 7, no. 2, pp. 146–157.
- Mirza, RE, Fang, MM, Weinheimer-Haus, EM, Ennis, WJ & Koh, TJ 2014, 'Sustained Inflammasome Activity in Macrophages Impairs Wound Healing in Type 2 Diabetic Humans and Mice', *Diabetes*, vol. 63, no. 3, pp. 1103–1114.
- MOE 2015, *Molecular Operating Environment*, Suite #910., Chemical Computing Group Inc., 1010 Sherbooke St., Canada.
- Mohamed, IN, Ishrat, T, Fagan, SC & El-Remessy, AB 2015, 'Role of Inflammasome Activation in the Pathophysiology of Vascular Diseases of the Neurovascular Unit', *Antioxidants & Redox Signaling*, vol. 22, no. 13, pp. 1188–1206.
- Mohanraj, K, Karthikeyan, BS, Vivek-Ananth, RP, Chand, RPB, Aparna, SR, Mangalapandi, P & Samal, A 2018, 'IMPPAT: A curated database of Indian

- Medicinal Plants, Phytochemistry And Therapeutics’, *Scientific Reports*, vol. 8, no. 1, p. 4329.
- Moltrasio, C, Romagnuolo, M & Marzano, AV 2022, ‘NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies’, *Frontiers in Immunology*, vol. 13, p. 1007705.
- Ning, B, Shen, J, Liu, F, Zhang, H & Jiang, X 2023, ‘Baicalein Suppresses NLRP3 and AIM2 Inflammasome-Mediated Pyroptosis in Macrophages Infected by *Mycobacterium tuberculosis* via Induced Autophagy’, S Prusic (ed.), *Microbiology Spectrum*, vol. 11, no. 3, pp. e04711-22.
- Ohto, U, Kamitsukasa, Y, Ishida, H, Zhang, Z, Murakami, K, Hirama, C, Maekawa, S & Shimizu, T 2022, ‘Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation’, *Proceedings of the National Academy of Sciences*, vol. 119, no. 11, p. e2121353119.
- Pantsar, T & Poso, A 2018, ‘Binding Affinity via Docking: Fact and Fiction’, *Molecules*, vol. 23, no. 8, p. 1899.
- Patel, S, Srivastava, S, Singh, MR & Singh, D 2019, ‘Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing’, *Biomedicine & Pharmacotherapy*, vol. 112, p. 108615.
- Ramírez, D & Caballero, J 2018, ‘Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?’, *Molecules*, vol. 23, no. 5, p. 1038.
- Ringbom, T, Huss, U, Stenholm, Å, Flock, S, Skattebøl, L, Perera, P & Bohlin, L 2001, ‘COX-2 Inhibitory Effects of Naturally Occurring and Modified Fatty Acids’, *Journal of Natural Products*, vol. 64, no. 6, pp. 745–749.
- Sailapathi, A, Murugan, G, Somarathinam, K, Gunalan, S, Jagadeesan, R, Yoosuf, N, Kanagaraj, S & Kothandan, G 2020, ‘Proposing the Promiscuous Protein Structures in JNK1 and JNK3 for Virtual Screening in Pursuit of Potential Leads’, *ACS Omega*, vol. 5, no. 8, pp. 3969–3978.
- Samuelson, AB 2000, ‘The traditional uses, chemical constituents and biological activities of *Plantago major* L. A review’, *Journal of Ethnopharmacology*, vol. 71, no. 1–2, pp. 1–21.
- Sharif, H, Wang, L, Wang, WL, Magupalli, VG, Andreeva, L, Qiao, Q, Hauenstein, AV, Wu, Z, Núñez, G, Mao, Y & Wu, H 2019, ‘Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome’, *Nature*, vol. 570, no. 7761, pp. 338–343.
- Sharma, A, Tate, M, Mathew, G, Vince, JE, Ritchie, RH & De Haan, JB 2018, ‘Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications’, *Frontiers in Physiology*, vol. 9, p. 114.
- Shi, A, Shi, H, Wang, Y, Liu, X, Cheng, Y, Li, H, Zhao, H, Wang, S & Dong, L 2018, ‘Activation of Nrf2 pathway and inhibition of NLRP3 inflammasome activation contribute to the protective effect of chlorogenic acid on acute liver injury’, *International Immunopharmacology*, vol. 54, pp. 125–130.
- Sobolev, OV, Afonine, PV, Moriarty, NW, Hekkelman, ML, Joosten, RP, Perrakis, A & Adams, PD 2020, ‘A Global Ramachandran Score Identifies Protein

- Structures with Unlikely Stereochemistry’, *Structure*, vol. 28, no. 11, pp. 1249-1258.e2.
- Song, M, Chen, Z, Qiu, R, Zhi, T, Xie, W, Zhou, Y, Luo, N, Fuqian Chen, Liu, F, Shen, C, Lin, S, Zhang, F, Gao, Y & Liu, C 2022, ‘Inhibition of NLRP3-mediated crosstalk between hepatocytes and liver macrophages by geniposidic acid alleviates cholestatic liver inflammatory injury’, *Redox Biology*, vol. 55, p. 102404.
- Spampinato, SF, Caruso, GI, De Pasquale, R, Sortino, MA & Merlo, S 2020, ‘The Treatment of Impaired Wound Healing in Diabetes: Looking among Old Drugs’, *Pharmaceuticals*, vol. 13, no. 4, p. 60.
- Sugiyarto, S, Setyawan, AD & Pitoyo, A 2006, ‘Estimation of abundance and distribution of *Plantago* major L. in Mount Lawu’, *Biodiversitas Journal of Biological Diversity*, vol. 7, no. 2, viewed 18 December 2023, <<https://smujo.id/biodiv/article/view/535>>.
- Swanson, KV, Deng, M & Ting, JP-Y 2019, ‘The NLRP3 inflammasome: molecular activation and regulation to therapeutics’, *Nature Reviews Immunology*, vol. 19, no. 8, pp. 477–489.
- Tapia-Abellán, A, Angosto-Bazarrá, D, Martínez-Banaclocha, H, De Torre-Minguela, C, Cerón-Carrasco, JP, Pérez-Sánchez, H, Arostegui, JI & Pelegrin, P 2019, ‘MCC950 closes the active conformation of NLRP3 to an inactive state’, *Nature Chemical Biology*, vol. 15, no. 6, pp. 560–564.
- Thomay, AA, Daley, JM, Sabo, E, Worth, PJ, Shelton, LJ, Harty, MW, Reichner, JS & Albina, JE 2009, ‘Disruption of Interleukin-1 Signaling Improves the Quality of Wound Healing’, *The American Journal of Pathology*, vol. 174, no. 6, pp. 2129–2136.
- Torres, PHM, Sodero, ACR, Jofily, P & Silva-Jr, FP 2019, ‘Key Topics in Molecular Docking for Drug Design’, *International Journal of Molecular Sciences*, vol. 20, no. 18, p. 4574.
- Uitdehaag, JC, Verkaar, F, Alwan, H, De Man, J, Buijsman, RC & Zaman, GJ 2012, ‘A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets’, *British Journal of Pharmacology*, vol. 166, no. 3, pp. 858–876.
- USDA *Plants Database* n.d., viewed 18 December 2023, <<https://plants.usda.gov/home/help>>.
- Utomo, RY, Ikawati, M & Meiyanto, E 2020, *Revealing the Potency of Citrus and Galangal Constituents to Halt SARS-CoV-2 Infection*, preprint, MEDICINE & PHARMACOLOGY, viewed 2 January 2024, <<https://www.preprints.org/manuscript/202003.0214/v1>>.
- Utomo, RY, Ikawati, M, Putri, DDP, Salsabila, IA & Meiyanto, E 2020, ‘The Chemopreventive Potential of Diosmin and Hesperidin for COVID-19 and Its Comorbid Diseases’, *Indonesian Journal of Cancer Chemoprevention*, vol. 11, no. 3, p. 154.
- Utomo, RY, Novarina, A, Tirtanirmala, P, Kastian, RF & Jenie, RI 2018, ‘Enhancement of Cytotoxicity and Apoptosis Induction of Doxorubicin by Brazilein Containing Fraction of Secang (*Caesalpinia sappan* L.) on T47D Cells’, *Indonesian Journal of Cancer Chemoprevention*, vol. 9, no. 1, p. 32.

- Utomo, RY, Putri, H, Pudjono, P, Susidarti, RA, Jenie, RI & Meiyanto, E 2017, 'SYNTHESIS AND CYTOTOXIC ACTIVITY OF 2,5-BIS(4-BORONIC ACID)BENZYLIDINE CYCLOPENTANONE ON HER2 OVEREXPRESSED-CANCER CELLS', *INDONESIAN JOURNAL OF PHARMACY*, vol. 28, no. 2, p. 74.
- Utomo, RY, Wulandari, F, Novitasari, D, Lestari, B, Susidarti, RA, Jenie, RI, Kato, J, Sardjiman, S & Meiyanto, E 2022, 'Preparation and Cytotoxic Evaluation of PGV-1 Derivative, CCA-1.1, as a New Curcumin Analog with Improved-Physicochemical and Pharmacological Properties', *Advanced Pharmaceutical Bulletin*, vol. 12, no. 3, pp. 603–612.
- Utomo, RY, Wulandari, F, Novitasari, D, Susidarti, RA, Kirihata, M, Hermawan, A & Meiyanto, E 2022, *Synthesis and cytotoxicity of the boron carrier*, vol. 13, no. 1.
- Vande Walle, L, Said, M, Paerewijck, O, Bertoni, A, Gattorno, M, Linclau, B & Lamkanfi, M 2024, 'Novel chemotype NLRP3 inhibitors that target the CRID3-binding pocket with high potency', *Life Science Alliance*, vol. 7, no. 6, p. e202402644.
- Vande Walle, L, Stowe, IB, Šácha, P, Lee, BL, Demon, D, Fossoul, A, Van Hauwermeiren, F, Saavedra, PHV, Šimon, P, Šubrt, V, Kostka, L, Stivala, CE, Pham, VC, Staben, ST, Yamazoe, S, Konvalinka, J, Kayagaki, N & Lamkanfi, M 2019, 'MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition', K Cadwell (ed.), *PLOS Biology*, vol. 17, no. 9, p. e3000354.
- Xiao, L, Magupalli, VG & Wu, H 2023, 'Cryo-EM structures of the active NLRP3 inflammasome disc', *Nature*, vol. 613, no. 7944, pp. 595–600.
- Yang, Y, Wang, H, Kouadir, M, Song, H & Shi, F 2019, 'Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors', *Cell Death & Disease*, vol. 10, no. 2, p. 128.
- Yu, X, Matico, RE, Miller, R, Chauhan, D, Van Schoubroeck, B, Grauwen, K, Suarez, J, Pietrak, B, Haloi, N, Yin, Y, Tresadern, GJ, Perez-Benito, L, Lindahl, E, Bottelbergs, A, Oehlrich, D, Van Opdenbosch, N & Sharma, S 2024, 'Structural basis for the oligomerization-facilitated NLRP3 activation', *Nature Communications*, vol. 15, no. 1, p. 1164.
- Zahid, A, Li, B, Kombe, AJK, Jin, T & Tao, J 2019, 'Pharmacological Inhibitors of the NLRP3 Inflammasome', *Frontiers in Immunology*, vol. 10, p. 2538.
- Zeng, X, Zhang, P, Wang, Y, Qin, C, Chen, S, He, W, Tao, L, Tan, Y, Gao, D, Wang, B, Chen, Z, Chen, W, Jiang, YY & Chen, YZ 2019, 'CMAUP: a database of collective molecular activities of useful plants', *Nucleic Acids Research*, vol. 47, no. D1, pp. D1118–D1127.
- Zhang, L, Ai, C, Bai, M, Niu, J & Zhang, Z 2022, 'NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy', *International Journal of Molecular Sciences*, vol. 23, no. 18, p. 10632.
- Zhang, Q, Yu, W, Lee, S, Xu, Q, Naji, A & Le, AD 2015, 'Bisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent

IL-1 β Mechanism', *Journal of Bone and Mineral Research*, vol. 30, no. 12, pp. 2300–2312.

Zhang, X, Dai, J, Li, L, Chen, H & Chai, Y 2017, 'NLRP3 Inflammasome Expression and Signaling in Human Diabetic Wounds and in High Glucose Induced Macrophages', *Journal of Diabetes Research*, vol. 2017, pp. 1–7.

Zhou, Y, Wang, W, Zhong, L, Wang, L, Ma, M, Tang, X, Li, Z, Wang, C, Gou, L, Zhang, T & Song, H 2022, 'Clinical and genetic spectrum of 14 cases of NLRP3-associated autoinflammatory disease (NLRP3-AID) in China and a review of the literature', *Orphanet Journal of Rare Diseases*, vol. 17, no. 1, p. 214.

Zubair, M n.d., *Genetic Variation, Biochemical Contents and Wound Healing Activity of *Plantago major**.